35:35

ICE-HBV Symposium | Kobe, Japan: Panel Discussion

10:19

ICE-HBV Symposium | Kobe, Japan: Company Talks on RNAi Drugs - Shay Salehi, GSK

20:51

ICE-HBV Symposium | Kobe, Japan: Scientific Talks - Julie Lucifora (France)

09:48

ICE-HBV Symposium | Kobe, Japan: Company Talks on RNAi Drugs - Florian Lempp, Vir Biotechnology

22:20

ICE-HBV Symposium | Kobe, Japan: Scientific Talks - Lena Allweiss (Germany)

15:49

ICE-HBV Symposium | Kobe, Japan: Scientific Talks - John Tavis, University of Saint Louis (USA)

02:37

ICE-HBV Symposium | Kobe, Japan: Opening Remark - Maura Dandri, Germany & Adam Gehring (Canada)

04:55

What does a cure therapy pipeline look like?

04:24

How do we sign up for HBV and HDV clinical trials? | HBV Cure FAQs

06:02

How safe are clinical trials and what should patients expect if they participate in one?

01:01:07

2022 HBV Cure Symposium Promises and challenges of immunotherapies - Part 2

01:45:24

2022 HBV Community Forum

39:08

2022 HBV Cure Symposium Promises and challenges of immunotherapies - Part 1

05:37

Clinical Trials: Why do we need them? What does Phase 1, 2, and 3 mean? | HBV Cure FAQs

06:50

How possible is a cure for Hepatitis B? | HBV Cure FAQs

06:24

What do we need to achieve a Hepatitis B Cure? | HBV Cure FAQs

05:19

What could a Hepatitis B cure look like? | HBV Cure FAQs

06:42

Hepatitis Commodities Access in Low & Middle Income Countries Talk at World Hepatitis Summit 2022

04:57

What do we mean by Hepatitis B cure? | HBV Cure FAQs

07:36

Why do we need a Hepatitis B cure? What are the benefits for patients? | HBV Cure FAQs

01:17:40

Webinar HBV Cure 101 Europe

16:59

ICE-HBV Cure Symposium 2021 Q&A Session Massimo Levrero, Grace Wong, & Heiner Wedemeyer

16:00

ICE-HBV Cure Symposium 2021 HBV and HDV cross utility for drug development

14:58

ICE-HBV Cure Symposium 2021 Flares in clinical trials: Who is good? Who is bad?

24:31

ICE-HBV Cure Symposium 2021 Use of novel biomarkers to assist combination trials

20:26

ICE-HBV Cure Symposium 2021 Q&A Session Haitao Guo, Adam Gehring, & Maura Dandri

17:28

ICE-HBV Cure Symposium 2021 - Pre-clinical evidence for combination strategies

17:46

ICE-HBV Cure Symposium 2021 Compound combos that stimulate & enhance HBV-specific B/T cells function

18:07

ICE-HBV Cure Symposium 2021 - Combinations of direct acting antivirals to decrease the cccDNA pool

56:23

Industry Discussion on Combination Therapy for Hepatitis B Cure at ICE HBV Toronto Symposium

01:33:04

Hepatitis B Community Forum at the 2021 International HBV Meeting (Toronto)

26:35

Seng Gee Lim (NUS Singapore) on HBV Science for the Community

05:25

Margaret Hellard (Burnet Institute) on Hepatitis B Health Care Access in Asia Pacific

04:59

HBV Functional Cure Q&As: For Hepatitis B what does functional cure mean?

10:59

Remarks From Lived Experience - Hepatitis B Community Webinar Asia Pacific

09:20

ICE-HBV Serum Biomarkers Workshop Session 2 - Concluding Remarks and Next Steps

48:17

ICE-HBV Serum Biomarkers Workshop Session 2 Industry Panel Discussion

17:36

ICE-HBV Serum Biomarkers Workshop - Relevance of biomarkers used in model systems to the clinic

18:14

ICE-HBV Serum Biomarkers Workshop - Point of Care Testing: an Unmet and Urgent Need

19:35

ICE-HBV Serum Biomarkers Workshop - Biomarkers of Liver Cancer

16:37

ICE-HBV Serum Biomarkers Workshop - Biomarkers of Occult HBV infection

17:51

ICE-HBV Serum Biomarkers Workshop - Biomakers of HBV cccDNA Expression

05:33

ICE-HBV Serum Biomarkers Workshop - Session 2 Welcome

41:39

ICE-HBV Serum Biomarkers Workshop Session 1 Industry Panel Discussion

03:02

A Hepatitis Story - World Hepatitis Day Video by ICE-HBV

24:14

ICE-HBV Serum Biomarkers Workshop - Utility of Serum Biomarkers

21:27

ICE-HBV Serum Biomarkers Workshop - What is Serum HBV RNA?

23:59

ICE-HBV Serum Biomarkers Workshop - Summary of the Immunological Serum Biomarker Landscape

19:23

ICE-HBV Serum Biomarkers Workshop - Summary of the Viral Serum Biomarker Landscape

05:26

ICE-HBV Serum Biomarkers Workshop 2020 Session 1 - Welcome and Aims